Constella: first-in-class treatment option for IBS patients with constipation

Almirall has launched Constella (linaclotide) for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation.

Constella (linaclotide) is a once-daily oral capsule that should be taken at least 30 minutes before a meal to reduce gastrointestinal adverse effects.
Constella (linaclotide) is a once-daily oral capsule that should be taken at least 30 minutes before a meal to reduce gastrointestinal adverse effects.


Linaclotide binds to the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium resulting in increased concentrations of both extra- and intra-cellular cyclic guanosine monophosphate (c-GMP).1 

Extracellular c-GMP decreases pain fibre activity thereby reducing visceral pain in animal models, while intracellular c-GMP causes secretion of chloride and bicarbonate into the intestinal lumen leading to increased intestinal fluid and accelerated transit.1


The efficacy and safety of linaclotide for the treatment of IBS-C was investigated in two randomised, double-blind, placebo-controlled phase III studies of similar design: study 1 (n=804) assessed patients over 26 weeks and study 2 (n=800) evaluated patients over 12 weeks before re-randomisation for an additional 4-week treatment period. In both studies, patients received linaclotide 290 microgram or placebo.1-3

Patients met Rome II criteria for IBS-C and were required to report a mean abdominal pain score of 3 or more on a 0–10 point numeric rating scale (criteria that correspond to a moderate to severe IBS population), <3 complete spontaneous bowel movements (SBMs and ≤5 SBMs per week during a 2-week baseline period.1

Investigators used IBS degree of relief response rate (considerably or completely relieved for ≥50% of treatment period) and abdominal pain/discomfort response rate (improvement of ≥30% for at least 50% of the treatment period) at 12 weeks as the co-primary endpoints.1

Pre-treatment, patients had a mean abdominal pain score of 5.6 and bloating score of 6.6 (0-10 scale) with 2.2% of days free of abdominal pain and an average of 1.8 SBMs per week.1

Reduction in IBS relief and abdominal pain/discomfort

In study 1, the IBS degree of relief response rate at 12 weeks was 33.7% in patients treated with linaclotide compared with 13.9% in patients on placebo (p<0.0001), and a further 48.9% of patients showed response to abdominal pain/discomfort comapred with 34.5% in the placebo arm.2

In study 2, patients treated with linaclotide had a IBS degree of relief response rate at week 12 of 33.6% versus 21% for patients on placebo (p<0.0001), and a greater percentage of patients given linaclotide showed a response in terms of abdominal pain/discomfort (50.1% vs 37.5% for placebo, p=0.0003).3

At 26 weeks in study 1, significantly higher percentages of linaclotide-treated patients showed a response in terms of IBS relief and abdominal pain/discomfort compared with patients on placebo: 37% and 54% for linaclotide and 17% and 36% for placebo, respectively (p<0.0001 for both comparisons).4

Other signs and symptoms of IBS-C including bloating, frequency of complete SBMs, straining and stool consistency were improved in linaclotide treated patients compared with those on placebo (p<0.0001). These effects were seen at 1 week and sustained over the entire treatment period.1

Safety profile


The most commonly reported adverse effect in both trials was diarrhoea. This resulted in discontinuation of linaclotide in 4.5% of linaclotide-treated patients compared with 0.2% of patients treated with placebo in study 1. Similar rates of discontinuation were observed in study 2: 5.7% for linaclotide versus 0.3% for placebo.2,3

Prescribers should advise patients to seek medical attention if diarrhoea is severe or prolonged (lasting over 1 week) and temporary discontinuation should be considered in this event.1


  1. Constella Summary of Product Characteristics, November 2012.
  2. Chey WD et al. Am J Gastroenterol 2012; 101: 1702–12.
  3. Rao S et al. Am J Gastroenterol 2012; 107: 1714–1724.
  4. Quigley EM et al. Aliment Pharmacol Ther 2013; 37: 49–61.

View Constella drug record

Further information:  Almirall

Follow MIMS on Twitter

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases